ADMA Biologics
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These spec...
Latest News
3 days ago · zacks.com
Here's Why Adma Biologics (ADMA) is a Strong Momentum StockWondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
5 days ago · zacks.com
Why Adma Biologics (ADMA) is a Top Growth Stock for the Long-TermThe Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
5 days ago · zacks.com
ADMA Surges 20.9% Post Q3 Earnings: Buy, Sell or Hold the Stock?ADMA Biologics gains 20.9% after strong Q3 results, as surging Asceniv sales and a raised 2026 profit outlook offset Bivigam weakness and competitive pressures.
11 days ago · zacks.com
Adma Biologics (ADMA) Just Overtook the 20-Day Moving AverageAfter reaching an important support level, Adma Biologics (ADMA) could be a good stock pick from a technical perspective. ADMA surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.
11 days ago · zacks.com
Adma Biologics (ADMA) Recently Broke Out Above the 200-Day Moving AverageFrom a technical perspective, Adma Biologics (ADMA) is looking like an interesting pick, as it just reached a key level of support. ADMA recently overtook the 200-day moving average, and this suggests a long-term bullish trend.
12 days ago · seekingalpha.com
ADMA Biologics, Inc. (ADMA) Q3 2026 Earnings Call TranscriptADMA Biologics, Inc. (ADMA) Q3 2026 Earnings Call Transcript
12 days ago · zacks.com
Adma Biologics (ADMA) Q3 Earnings and Revenues Beat EstimatesAdma Biologics (ADMA) came out with quarterly earnings of $0.22 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.16 per share a year ago.
12 days ago · marketbeat.com
ADMA Biologics Q3 Earnings Call HighlightsADMA Biologics NASDAQ: ADMA raised its minimum full-year earnings expectations after third-quarter profit rose on stronger sales of ASCENIV and improved manufacturing yields, even as competitive pressure weighed on its BIVIGAM product.
17 days ago · zacks.com
Adma Biologics (ADMA) Registers a Bigger Fall Than the Market: Important Facts to NoteIn the closing of the recent trading day, Adma Biologics (ADMA) stood at $11.41, denoting a -2.89% move from the preceding trading day.
19 days ago · zacks.com
Brokers Suggest Investing in Adma Biologics (ADMA): Read This Before Placing a BetWhen deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove ADMA